Overall, a deeper understanding of immune cell-biomarker correlations may provide new insights into immune mechanisms, and targeting CTSS, LYZ, and ISG20 to improve abnormal immune status may be a promising method for treating CKD. This evidence concerns the gene CTSS and chronic kidney disease.